• Info
  • Insider Trading

Insider Transactions Reported by 16 Insiders of Generate Biomedicines, Inc.

Symbol
GENB
Location
Somerville, MA

There are no Buy or Sell transactions made by insiders since 14 Mar 2025

Generate Biomedicines, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Marsha Fanucci Director 26 Feb 2026
Frances H. Arnold Director 26 Feb 2026
Aarif Khakoo Chief Scientific Officer 26 Feb 2026
Rupert Vessey Director 26 Feb 2026
Stephane Bancel Director 26 Feb 2026
Beth Grous Chief People Officer 26 Feb 2026
Gevorg Grigoryan Chief Technology Officer 26 Feb 2026
Laurie Anne Lee Chief Medical Officer 26 Feb 2026
Jane L. Mendillo Director 26 Feb 2026
Nancy A. Simonian Director 26 Feb 2026
Paul Gray Parker Director 26 Feb 2026
Jason Silvers President & CFO 26 Feb 2026
Sean Martin Chief Legal Officer & GC 26 Feb 2026
Michael Nally Chief Executive Officer, Director 04 Mar 2026
Ph.D. Noubar B. Afeyan Director, 10%+ Owner 26 Feb 2026
Pioneering Medicines 02, LLC 10%+ Owner 02 Mar 2026

Recent Insider Transactions by Companies or Individuals for Generate Biomedicines, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Michael Nally GENB Common Stock Purchase 3.62% 20,000 572,707 04 Mar 2026 Direct
Beth Grous GENB Common Stock Purchase 300 300 02 Mar 2026 By Spouse
Jason Silvers GENB Common Stock Purchase 1,000 1,000 02 Mar 2026 By son
Jason Silvers GENB Common Stock Purchase 1,000 500 02 Mar 2026 By daughter
Ph.D. Noubar B. Afeyan GENB Common Stock Purchase 1,562,500 1,562,500 02 Mar 2026 By Pioneering Medicines 02, LLC
Ph.D. Noubar B. Afeyan GENB Common Stock Purchase 56.2% 1,562,500 4,340,252 02 Mar 2026 By FPN II, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Purchase 11.4% 1,562,500 15,264,724 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 2,777,752 2,777,752 02 Mar 2026 By FPN II, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 2,777,752 2,777,752 02 Mar 2026 By Flagship Pioneering Special Opportunities Fund II, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 987,491 987,491 02 Mar 2026 By Nutritional Health LTP Fund, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 13,702,224 13,702,224 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 12,723,940 12,723,940 02 Mar 2026 By Flagship Pioneering Fund VI, L.P.
Ph.D. Noubar B. Afeyan GENB Series C Preferred Stock Conversion of derivative security -100% -2,109,704 0 02 Mar 2026 By FPN II, L.P.
Ph.D. Noubar B. Afeyan GENB Series C Preferred Stock Conversion of derivative security -100% -1,265,822 0 02 Mar 2026 By Flagship Pioneering Special Opportunities Fund II, L.P.
Ph.D. Noubar B. Afeyan GENB Series C Preferred Stock Conversion of derivative security -100% -2,531,644 0 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Series B Preferred Stock Conversion of derivative security -100% -2,109,704 0 02 Mar 2026 By FPN II, L.P.
Ph.D. Noubar B. Afeyan GENB Series B Preferred Stock Conversion of derivative security -100% -2,953,586 0 02 Mar 2026 By Flagship Pioneering Special Opportunities Fund II, L.P.
Ph.D. Noubar B. Afeyan GENB Series B Preferred Stock Conversion of derivative security -100% -1,265,822 0 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Series B Preferred Stock Conversion of derivative security -100% -843,881 0 02 Mar 2026 By Flagship Pioneering Fund VI, L.P.
Ph.D. Noubar B. Afeyan GENB Series A Preferred Stock Conversion of derivative security -100% -1,500,000 0 02 Mar 2026 By Nutritional Health LTP Fund, L.P.
Ph.D. Noubar B. Afeyan GENB Series A Preferred Stock Conversion of derivative security -100% -17,016,215 0 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Series A Preferred Stock Conversion of derivative security -100% -18,483,785 0 02 Mar 2026 By Flagship Pioneering Fund VI, L.P.
Michael Nally GENB Common Stock Conversion of derivative security 100% 658,327 1,316,654 02 Mar 2026 By MTN 2024 GST Trust
Michael Nally GENB Series A Preferred Stock Conversion of derivative security -100% -1,000,000 0 02 Mar 2026 By MTN 2024 GST Trust
Stephane Bancel GENB Common Stock Conversion of derivative security 724,160 724,160 02 Mar 2026 By OCHA LLC
Stephane Bancel GENB Series A Preferred Stock Conversion of derivative security -100% -1,100,000 0 02 Mar 2026 By OCHA LLC
Jane L. Mendillo GENB Common Stock Purchase 1,500 1,500 02 Mar 2026 Direct
Ph.D. Noubar B. Afeyan GENB Common Stock Purchase 1,562,500 1,562,500 02 Mar 2026 By Pioneering Medicines 02, LLC
Ph.D. Noubar B. Afeyan GENB Common Stock Purchase 56.2% 1,562,500 4,340,252 02 Mar 2026 By FPN II, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Purchase 11.4% 1,562,500 15,264,724 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 2,777,752 2,777,752 02 Mar 2026 By FPN II, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 2,777,752 2,777,752 02 Mar 2026 By Flagship Pioneering Special Opportunities Fund II, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 987,491 987,491 02 Mar 2026 By Nutritional Health LTP Fund, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 13,702,224 13,702,224 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Common Stock Conversion of derivative security 12,723,940 12,723,940 02 Mar 2026 By Flagship Pioneering Fund VI, L.P.
Ph.D. Noubar B. Afeyan GENB Series C Preferred Stock Conversion of derivative security -100% -2,109,704 0 02 Mar 2026 By FPN II, L.P.
Ph.D. Noubar B. Afeyan GENB Series C Preferred Stock Conversion of derivative security -100% -1,265,822 0 02 Mar 2026 By Flagship Pioneering Special Opportunities Fund II, L.P.
Ph.D. Noubar B. Afeyan GENB Series C Preferred Stock Conversion of derivative security -100% -2,531,644 0 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Series B Preferred Stock Conversion of derivative security -100% -2,109,704 0 02 Mar 2026 By FPN II, L.P.
Ph.D. Noubar B. Afeyan GENB Series B Preferred Stock Conversion of derivative security -100% -2,953,586 0 02 Mar 2026 By Flagship Pioneering Special Opportunities Fund II, L.P.
Ph.D. Noubar B. Afeyan GENB Series B Preferred Stock Conversion of derivative security -100% -1,265,822 0 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Series B Preferred Stock Conversion of derivative security -100% -843,881 0 02 Mar 2026 By Flagship Pioneering Fund VI, L.P.
Ph.D. Noubar B. Afeyan GENB Series A Preferred Stock Conversion of derivative security -100% -1,500,000 0 02 Mar 2026 By Nutritional Health LTP Fund, L.P.
Ph.D. Noubar B. Afeyan GENB Series A Preferred Stock Conversion of derivative security -100% -17,016,215 0 02 Mar 2026 By Flagship Pioneering Fund VII, L.P.
Ph.D. Noubar B. Afeyan GENB Series A Preferred Stock Conversion of derivative security -100% -18,483,785 0 02 Mar 2026 By Flagship Pioneering Fund VI, L.P.
Rupert Vessey GENB Stock Option (Right to Buy) Award 29,561 29,561 26 Feb 2026 Direct
Beth Grous GENB Stock Option (Right to Buy) Award 114,020 114,020 26 Feb 2026 Direct
Frances Arnold GENB Stock Option (Right to Buy) Award 29,561 29,561 26 Feb 2026 Direct
Laurie Anne Lee GENB Stock Option (Right to Buy) Award 42,230 42,230 26 Feb 2026 Direct
Sean Martin GENB Stock Option (Right to Buy) Award 190,034 190,034 26 Feb 2026 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.